Brought to you by 
Series B brings in $12.5mm for Molecular Biometrics
02 Feb 2010
Executive Summary
Molecular Biometrics (diagnostics for cardiovascular, gynecological, and neurological use) has raised $12.5mm through its Series B venture round. New backer Atlas Venture led and was joined by current shareholders Safeguard Scientifics and Oxford Bioscience Partners. Funds will be used to complete an ongoing FDA clinical study of and launch its ViaMetrics-E, a noninvasive procedure to help identify viable embryos and potentially improve the success rate of in vitro fertilization.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $12.5mm for Molecular Biometrics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice